Large-Scale, Deep, and Unbiased Plasma Proteomics for a Multi-Cancer Biomarker Discovery Study скачать в хорошем качестве

Large-Scale, Deep, and Unbiased Plasma Proteomics for a Multi-Cancer Biomarker Discovery Study

Bruce Wilcox, VP of Proteomics at PrognomiQ, Inc., presents data from a biomarker discovery feasibility study of 212 subjects (cancer vs non-cancer) that demonstrates how the Proteograph™ Product Suite, combined with the timsTOF Pro2, creates deep proteome coverage at high throughput with reproducibility for large-scale proteomics studies. PrognomiQ’s uses a multi-omics platform for interrogating complex diseases, with proteomics playing an important role. Watch how the Proteograph Product Suite has provided enhanced proteome coverage to detect known cancer-related proteins at eight orders of magnitude, helping drive innovation in cancer detection and care. A presentation from HUPO Reconnect 2021. === Key Topics === 0:00 – Introduction 2:05 – Early cancer detection innovations 3:10 – PrognomiQ’s approach 5:25 – Evaluation of the Proteograph Product Suite and timsTOF Pro2 9:10 – The detection of more than 5,000 proteins 11:25 – Configuring a robust Proteograph workflow with LC-MS 18:45 – Data from a multi-cancer study 19:55 – Conclusion and acknowledgements === Resources === ✭ Visit Seer’s Scientific Presentations Playlist:    • Scientific Presentations   === Stay Connected With Seer === ✭ To learn how Seer is empowering the scientific community through the power of proteomics, visit: https://seer.bio ✭ Subscribe to Seer’s YouTube channel for more on proteomics analysis and innovations https://www.youtube.com/c/SeerInc?sub... ✭ Join Seer on LinkedIn   / seerbio   ✭ Join Seer on Twitter   / seer_bio   #Seer #proteomics #proteomicsanalysis #SeerBiotech #plasmaproteomics #Proteograph #AskSeerScientists #lcms #unbiasedproteomics #nextgenproteomics #PrognomiQ